Table 3

Edmonton comparison of academic with community-based hospitals

VTE specifiedEdmonton academic sitesEdmonton community-based sitesP values
VTE (all combined)p=0.0004
 Parenteral anticoagulant alone100 (60.6%)57 (41.0%)
 Parenteral anticoagulant+warfarin28 (17.0%)24 (17.3%)
 DOAC34 (20.6%)56 (40.3%)
  Rivaroxaban31 (91.2%)56 (100.0%)
  Apixaban3 (8.8%)0
 Not documented3 (1.8%)2 (1.4%)
PE and PE+DVTp=0.0039
 Parenteral anticoagulant alone45 (60.0%)19 (33.3%)
 Parenteral anticoagulant+warfarin6 (8.0%)12 (21.1%)
 DOAC21 (28.0%)25 (43.9%)
  Rivaroxaban19 (90.5%)25 (100.0%)
  Apixaban2 (9.5%)0
 Not documented3 (4.0%)1 (1.8%)
DVT alonep=0.0015
 Parenteral anticoagulant alone55 (61.1%)38 (46.3%)
 Parenteral anticoagulant+warfarin22 (24.4%)12 (14.6%)
 DOAC13 (14.4%)31 (37.8%)
  Rivaroxaban12 (92.3%)31 (100.0%)
  Apixaban1 (7.69)0
 Not documented01 (1.2%)
Follow-up*
 Family doctor22 (13.3%)39 (28.1%)
 Return to ED1 (0.6%)4 (2.9%)
 Specialist4 (2.4%)9 (6.5%)
 VTE clinic133 (80.6%)47 (33.8%)
 Anticoagulation clinic3 (1.8%)0
 Other8 (4.9%)36 (25.9%)
 Not documented3 (1.8%)20 (14.4%)
  • *Not mutually exclusive.

  • DOAC, direct oral anticoagulant; DVT, deep vein thrombosis; ED, emergency department; PE, pulmonary embolism; VTE, venous thromboembolism.